S&P 500   3,211.61 (-0.46%)
DOW   26,715.40 (-0.58%)
QQQ   258.82 (-0.80%)
AAPL   386.04 (-1.24%)
MSFT   204.08 (-1.90%)
FB   240.03 (-0.10%)
GOOGL   1,507.14 (-0.64%)
AMZN   3,016.53 (+0.25%)
NVDA   405.65 (-0.84%)
CGC   17.90 (-1.38%)
BABA   244.41 (-1.93%)
MU   50.09 (-0.83%)
GE   7.11 (-0.42%)
TSLA   1,525.25 (-1.34%)
AMD   54.54 (-1.45%)
T   30.30 (+0.97%)
ACB   12.06 (-6.29%)
F   6.84 (+1.48%)
GILD   76.16 (-0.64%)
DIS   119.38 (-1.28%)
NFLX   527.15 (+0.74%)
BAC   23.90 (-2.85%)
BA   181.23 (-3.57%)
S&P 500   3,211.61 (-0.46%)
DOW   26,715.40 (-0.58%)
QQQ   258.82 (-0.80%)
AAPL   386.04 (-1.24%)
MSFT   204.08 (-1.90%)
FB   240.03 (-0.10%)
GOOGL   1,507.14 (-0.64%)
AMZN   3,016.53 (+0.25%)
NVDA   405.65 (-0.84%)
CGC   17.90 (-1.38%)
BABA   244.41 (-1.93%)
MU   50.09 (-0.83%)
GE   7.11 (-0.42%)
TSLA   1,525.25 (-1.34%)
AMD   54.54 (-1.45%)
T   30.30 (+0.97%)
ACB   12.06 (-6.29%)
F   6.84 (+1.48%)
GILD   76.16 (-0.64%)
DIS   119.38 (-1.28%)
NFLX   527.15 (+0.74%)
BAC   23.90 (-2.85%)
BA   181.23 (-3.57%)
S&P 500   3,211.61 (-0.46%)
DOW   26,715.40 (-0.58%)
QQQ   258.82 (-0.80%)
AAPL   386.04 (-1.24%)
MSFT   204.08 (-1.90%)
FB   240.03 (-0.10%)
GOOGL   1,507.14 (-0.64%)
AMZN   3,016.53 (+0.25%)
NVDA   405.65 (-0.84%)
CGC   17.90 (-1.38%)
BABA   244.41 (-1.93%)
MU   50.09 (-0.83%)
GE   7.11 (-0.42%)
TSLA   1,525.25 (-1.34%)
AMD   54.54 (-1.45%)
T   30.30 (+0.97%)
ACB   12.06 (-6.29%)
F   6.84 (+1.48%)
GILD   76.16 (-0.64%)
DIS   119.38 (-1.28%)
NFLX   527.15 (+0.74%)
BAC   23.90 (-2.85%)
BA   181.23 (-3.57%)
S&P 500   3,211.61 (-0.46%)
DOW   26,715.40 (-0.58%)
QQQ   258.82 (-0.80%)
AAPL   386.04 (-1.24%)
MSFT   204.08 (-1.90%)
FB   240.03 (-0.10%)
GOOGL   1,507.14 (-0.64%)
AMZN   3,016.53 (+0.25%)
NVDA   405.65 (-0.84%)
CGC   17.90 (-1.38%)
BABA   244.41 (-1.93%)
MU   50.09 (-0.83%)
GE   7.11 (-0.42%)
TSLA   1,525.25 (-1.34%)
AMD   54.54 (-1.45%)
T   30.30 (+0.97%)
ACB   12.06 (-6.29%)
F   6.84 (+1.48%)
GILD   76.16 (-0.64%)
DIS   119.38 (-1.28%)
NFLX   527.15 (+0.74%)
BAC   23.90 (-2.85%)
BA   181.23 (-3.57%)
Log in

NASDAQ:SPROSpero Therapeutics Stock Price, Forecast & News

$12.85
-0.55 (-4.10 %)
(As of 07/16/2020 01:37 PM ET)
Add
Compare
Today's Range
$12.85
Now: $12.85
$13.11
50-Day Range
$11.82
MA: $12.96
$14.18
52-Week Range
$5.25
Now: $12.85
$14.48
Volume2,971 shs
Average Volume181,628 shs
Market Capitalization$264.58 million
P/E RatioN/A
Dividend YieldN/A
Beta1.97
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Spero Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SPRO
CUSIPN/A
Phone857-242-1600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.15 million
Book Value$3.90 per share

Profitability

Net Income$-60,920,000.00
Net Margins-654.03%

Miscellaneous

Employees57
Market Cap$264.58 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive SPRO News and Ratings via Email

Sign-up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.

Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions

How has Spero Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Spero Therapeutics' stock was trading at $7.75 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SPRO shares have increased by 65.8% and is now trading at $12.85. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Spero Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Spero Therapeutics.

When is Spero Therapeutics' next earnings date?

Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Spero Therapeutics.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics Inc (NASDAQ:SPRO) released its quarterly earnings data on Friday, May, 8th. The company reported ($1.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.35) by $0.13. The company earned $1.70 million during the quarter, compared to analyst estimates of $3.36 million. Spero Therapeutics had a negative return on equity of 88.22% and a negative net margin of 654.03%. View Spero Therapeutics' earnings history.

What price target have analysts set for SPRO?

6 brokers have issued 1-year price objectives for Spero Therapeutics' shares. Their forecasts range from $20.00 to $28.00. On average, they expect Spero Therapeutics' stock price to reach $23.00 in the next year. This suggests a possible upside of 79.0% from the stock's current price. View analysts' price targets for Spero Therapeutics.

Has Spero Therapeutics been receiving favorable news coverage?

Media headlines about SPRO stock have trended somewhat negative this week, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Spero Therapeutics earned a daily sentiment score of -1.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Spero Therapeutics.

Are investors shorting Spero Therapeutics?

Spero Therapeutics saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 623,200 shares, an increase of 8.0% from the June 15th total of 577,300 shares. Based on an average daily trading volume, of 168,000 shares, the days-to-cover ratio is presently 3.7 days. Currently, 4.3% of the company's shares are sold short. View Spero Therapeutics' Current Options Chain.

Who are some of Spero Therapeutics' key competitors?

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Crispr Therapeutics (CRSP), Viking Therapeutics (VKTX), Inovio Pharmaceuticals (INO), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), NVIDIA (NVDA), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), Nokia Oyj (NOK) and Akoustis Technologies (AKTS).

Who are Spero Therapeutics' key executives?

Spero Therapeutics' management team includes the following people:
  • Dr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 39, Pay $747.88k)
  • Ms. Cristina Larkin, Chief Operating Officer (Age 50, Pay $552.96k)
  • Dr. David A. Melnick M.D., Chief Medical Officer (Age 68, Pay $545.96k)
  • Mr. Stephen J. DiPalma M.B.A., Interim CFO & Treasurer (Age 61)
  • Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 66)

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

How do I buy shares of Spero Therapeutics?

Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $12.85.

How big of a company is Spero Therapeutics?

Spero Therapeutics has a market capitalization of $264.58 million and generates $18.15 million in revenue each year. The company earns $-60,920,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Spero Therapeutics employs 57 workers across the globe.

What is Spero Therapeutics' official website?

The official website for Spero Therapeutics is sperotherapeutics.com.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.